Tolvaptan
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Key Facts
Indication
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase
Approved
Status
Post-marketing studies
Company
About Otsuka Holdings
Otsuka Holdings is a multinational healthcare leader founded on the mission 'Otsuka-people creating new products for better health worldwide.' It has achieved global prominence through flagship CNS drugs, a strategic stake in Lundbeck, and blockbuster nutraceutical brands like Pocari Sweat. The company's strategy is built on a diversified four-pillar business model—pharmaceuticals, nutraceuticals, medical devices, and chemicals—driven by a unique culture of creativity ('Souzoususei') and evidence-based validation ('Jisshou').
View full company profileOther Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxypurinol (XRX-OXY) | XORTX Therapeutics | Phase 3 |
| Undisclosed | GondolaBio | IND Enabling |
| Undisclosed Program | Calico | Phase 2 |
| Small Molecule Corrector Program | Renasant Bio | Pre-clinical |
| Small Molecule Potentiator Program | Renasant Bio | Pre-clinical |
| AL1311 | AceLink Therapeutics | Preclinical |
| PDE4 Allosteric Modulator Program | Mironid | Pre-clinical |
| PXL-770 | Scynexis | Phase 2-ready |